Zenith Capital Corp. (ZHCLF)

Market Cap	16.11M +1.1%
Revenue (ttm)	n/a
Net Income	-9.14M
EPS	-0.06
Shares Out	161.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,101
Open	0.0500
Previous Close	0.1000
Day's Range	0.0500 - 0.1000
52-Week Range	0.0003 - 0.1900
Beta	626.84
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 2, 2026

About Zenith Capital

Zenith Capital Corp., a biotechnology investment company, develops bromodomain (BET) inhibitors for the treatment of cancer and other disorders with unmet medical needs in Canada. The company’s lead compound ZEN-3694, which is in Phase 2b clinical trial for the treatment of metastatic castration resistant prostate cancer, as well as for NUT carcinoma, solid tumors, breast and metastatic cancer, ovarian and colorectal cancer, lung and pancreatic cancer, and malignant peripheral nerve sheath tumors. It has collaborations with the National Cancer ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: ZHCLF

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 1, 2026

Data Sources Report a data error